var data={"title":"Erythromycin (topical): Drug information \t","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Erythromycin (topical): Drug information \t</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/393350?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=erythromycin-topical-patient-drug-information\" class=\"drug drug_patient\">see &quot;Erythromycin (topical): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=erythromycin-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Erythromycin (topical): Pediatric drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086237\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Akne-Mycin [DSC];</li>\n      <li>Ery;</li>\n      <li>Erygel</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086238\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Erysol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8089314\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Acne Products;</li>\n      <li>\n        Antibiotic, Macrolide;</li>\n      <li>\n        Antibiotic, Topical;</li>\n      <li>\n        Topical Skin Product;</li>\n      <li>\n        Topical Skin Product, Acne</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086396\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Akne-Mycin ointment has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Acne:</b> Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel: Apply sparingly as a thin film over the affected area once or twice daily. Therapeutic response may take up to 6-8 weeks; discontinue use if no improvement after 6-8 weeks or if condition worsens.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, solution: Apply  to affected area twice daily (morning and evening); drying and peeling may be controlled by reducing the frequency of application. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pads: Rub pad over affected areas twice daily (morning and evening); additional pads may be used, if needed. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Erysol [Canadian product]: Apply thin film to affected area twice daily (morning and evening after the skin has been thoroughly washed and patted dry); may decrease to once daily if irritation develops at application site. Therapeutic response may take up to 6-8 weeks; discontinue use if no improvement after 6-8 weeks or if condition worsens. Maximum therapy duration: 3 months. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086395\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=erythromycin-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Erythromycin (topical): Pediatric drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Akne-Mycin ointment has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b> Acne:</b> Children &ge;12 years and Adolescents: Topical: Erysol gel [Canadian product]: Apply thin film to affected area twice daily (morning and evening); may decrease to once daily if irritation develops at application site. Therapeutic response may take up to 6-8 weeks; discontinue use if no improvement after 6-8 weeks or if condition worsens. Maximum therapy duration: 3 months.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086397\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20302637\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20302638\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086447\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Erygel: 2% (30 g, 60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2% (30 g, 60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Akne-Mycin: 2% (25 g [DSC]) [contains cetostearyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pad, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ery: 2% (60 ea) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2% (60 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2% (60 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086240\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086448\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel, topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Erysol: 2% (25 g) [contains ethanol, octinoxate and avobenzone]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46374047\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Akne-Mycin ointment has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20302640\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Topical: Prior to treatment, thoroughly wash affected area with mild soap and warm water, rinse, and pat dry. Discard pad after single use. Wash hands after use. Avoid contact with the eyes, nose, mouth and other mucous membranes, and broken skin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086241\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">\n      <b>Acne:</b> Treatment of acne vulgaris</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8085307\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Erythromycin may be confused with azithromycin, clarithromycin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086294\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Desquamation, erythema, exfoliation of skin, oily skin, pruritus, rough skin (leather appearance), skin fissure (around mouth), skin tenderness, urticaria, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Application site irritation (includes local dryness, localized burning, localized erythema, localized tenderness, stinging of the skin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Eye irritation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Abdominal distress, abdominal pain, diarrhea, facial edema, hypersensitivity reaction, skin rash</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086279\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to erythromycin or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for erythromycin is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20302595\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Discontinue if significant diarrhea, abdominal cramps, or passage of blood and mucus occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Concurrent topical acne therapy: Use with caution especially with peeling, desquamating or abrasive agents; irritation may be cumulative. Discontinue use if irritation or dermatitis occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Topical gel: May be flammable. Keep away from heat and flame.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For topical use only; not for ophthalmic use. Avoid contact with eyes, nose, mouth, mucous membranes, or broken skin. Lack of improvement or worsening of acne may indicate microbial resistance. Alternative therapy may be required for severe acne (eg, nodular). Consider alternate therapy in patients with poor tolerance to macrolides or clindamycin. In the treatment of acne, American Academy of Dermatology acne guidelines recommend erythromycin (topical) be used in conjunction with other therapies (<i>not</i> as monotherapy) due to the risk of bacterial resistance. If given for mild acne, erythromycin (topical) should be used in combination with benzoyl peroxide. If given for moderate to severe acne, it should be used in combination with a topical retinoid or systemic antibiotic agent (AAD [Zaenglein 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299282\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086299\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9119&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Clindamycin (Topical): Erythromycin (Topical) may diminish the therapeutic effect of Clindamycin (Topical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isotretinoin (Topical): May enhance the adverse/toxic effect of Erythromycin (Topical).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086242\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9793457\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Erythromycin has been shown to cross the placenta following oral dosing. Refer to the Erythromycin (Systemic) monograph for details. The amount of erythromycin available systemically following topical application is considered to be very low (Akhavan, 2003). Systemic absorption would be required in order for erythromycin to cross the placenta and reach the fetus. Topical erythromycin may be used for the treatment of acne in pregnancy (Dr&eacute;no, 2013; Eichenfield, 2013; Gollnick, 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9793460\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if erythromycin is excreted into breast milk following topical application. The manufacturer recommends that caution be exercised when administering to nursing women. Erythromycin has been shown to enter breast milk following oral dosing. Refer to the Erythromycin (Systemic) monograph for details. The amount of erythromycin available systemically following topical application is considered to be very low (Akhavan, 2003). Systemic absorption would be required in order for erythromycin to enter breast milk and reach the nursing infant.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8089427\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Antibacterial activity is due to inhibition of RNA-dependent protein synthesis at the chain elongation step; binds to the 50S ribosomal subunit resulting in blockage of transpeptidation. Alcohol component induces skin drying and peeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086450\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Erygel External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (30 g): $209.71</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Erythromycin External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (30 g): $155.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pads</b> (Erythromycin External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (60): $94.55</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Erythromycin External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (60 mL): $50.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12707703\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>A Mycin (BD);</li>\n      <li>Acne Hermal (GR);</li>\n      <li>Acnederm (IN);</li>\n      <li>Acnederm Ery Gel (DE);</li>\n      <li>Acnefug-EL (CZ, EE, LV);</li>\n      <li>Acneryne (BE);</li>\n      <li>Acnetrim (IL, TW);</li>\n      <li>Akne-Mycin (AE, HK, IL, JO, MY, NL, PT, QA, SG, SI);</li>\n      <li>Aknemycin (BE, CZ, DE);</li>\n      <li>Aknilox (CH, TR);</li>\n      <li>Bonac Gel (PE);</li>\n      <li>Deripil Gel (ES);</li>\n      <li>Egery (FR);</li>\n      <li>Elimicina Dermica (PY);</li>\n      <li>Erazit (LK);</li>\n      <li>Eryacne (AR, CO, FR, GR, IT, KR, NZ, PY, SG, VE);</li>\n      <li>Eryacnen (BR, CL, CR, DO, GT, HN, NI, PA, PE, SV);</li>\n      <li>Eryaknen (CH);</li>\n      <li>Erycine (LB);</li>\n      <li>Eryderm (AE, NL, QA, SA);</li>\n      <li>Erydermec (DE);</li>\n      <li>Eryfluid (CZ, FR, LB, LU, RO);</li>\n      <li>Erylik (HK);</li>\n      <li>Erymed (ID);</li>\n      <li>Erymex Lotion (BD);</li>\n      <li>Erythromycine (LB);</li>\n      <li>Iloticina (AR, CO);</li>\n      <li>Ilotycin T.S. (ZA);</li>\n      <li>Inderm Gel (BE, DE);</li>\n      <li>Loderm Gel (ES);</li>\n      <li>Sansacne (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Stiemycin (AE, BR, CY, GB, IE, JO, KR, LB, LK, NZ, SG, TH, UY, ZA);</li>\n      <li>Stimycine (BE, FR);</li>\n      <li>Zineryt (MT, SI)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Akhavan A and Bershad S, &quot;Topical Acne Drugs: Review of Clinical Properties, Systemic Exposure, and Safety,&quot; <i>Am J Clin Dermatol</i>, 2003, 4(7):473-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-topical-drug-information/abstract-text/12814337/pubmed\" target=\"_blank\" id=\"12814337\">12814337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Akne-mycin (erythromycin) [prescribing information]. Fort Worth, TX: Coria Laboratories. <a href=\"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=720512c7-9ea4-40c8-b119-b39a3f9a448b\" target=\"_blank\">http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=720512c7-9ea4-40c8-b119-b39a3f9a448b</a>. Accessed April 2, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dr&eacute;no B, Layton A, Zouboulis CC, et al. Adult female acne: a new paradigm. <i>J Eur Acad Dermatol Venereol</i>. 2013;27(9):1063-1070.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-topical-drug-information/abstract-text/23302006/pubmed\" target=\"_blank\" id=\"23302006\">23302006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. <i>Pediatrics</i>. 2013;131 (Suppl 3):S163-186.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-topical-drug-information/abstract-text/23637225/pubmed\" target=\"_blank\" id=\"23637225\">23637225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ery Pads (erythromycin) [prescribing information]. Allegan, MI: Perrigo; August 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erygel (erythromycin) [prescribing information]. Newtown, PA: Prestium Pharma; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gollnick H, Cunliffe W, Berson D, et al, &quot;Management of Acne: A Report From a Global Alliance to Improve Outcomes in Acne,&quot; <i>J Am Acad Dermatol</i>, 2003, 49(1 Suppl):S1-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-topical-drug-information/abstract-text/12833004/pubmed\" target=\"_blank\" id=\"12833004\">12833004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33. http://www.jaad.org/article/S0190-9622(15)02614-6/pdf. Accessed June 13, 2016.26897386</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9119 Version 130.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8086237\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8086238\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8089314\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8086396\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F8086395\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8086397\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F20302637\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20302638\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8086447\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8086240\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F8086448\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F46374047\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F20302640\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8086241\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8085307\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8086294\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8086279\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F20302595\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299282\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8086299\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8086242\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9793457\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9793460\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8089427\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8086450\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F12707703\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9119|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=erythromycin-topical-patient-drug-information\" class=\"drug drug_patient\">Erythromycin (topical): Patient drug information \t</a></li><li><a href=\"topic.htm?path=erythromycin-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">Erythromycin (topical): Pediatric drug information \t</a></li></ul></div></div>","javascript":null}